Glaxosmithkline Biologicals Sa

Janssen Pharmaceuticals, Inc.

Glycovaxyn Ag

Stefan Jochen Kemmler

Michael T Kowarik

Manuela Mally

Michael L Wetter

Darren Robert Abbanat

Micha Andres Häuptle

Veronica Gambillara Fonck

Patricia Ibarra Yon

Veronica Gambillara

Jeroen Geurtsen

Amirreza Faridmoayer

Eveline Marleen Weerdenburg

Martin Edward Braun

Jan Theunis Poolman

Pieter Jan Burghout

Maria Paula Carranza Sandmeier

Jan Poolman

Fabio Serventi

Peter Wilhelmus Maria Hermans

Bert Jacquemyn

Gerald Johann Posch

Rainer Follador

Kellen Cristhina Fae

Gerd Martin Lipowsky

Christiane Marie-Paule Simone Jeanne Feron

Sabina Marietta Gerber

Julien Laurent Quebatte

Micha A Häuptle

Leigh Anne Ihnken

Joel Melby

Anne Ollis

Michael Thomas Kowarik

Julien L Quebatte

Micha A Hauptle

Michael Lukas Wetter

Micha Andres Hauptle

Fonck Veronica Gambillara

Julien L QUÉBATTE

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic. (ExPEC).

Methods of producing bioconjugates ofO-antigen polysaccharides, compositions thereof, and methods of use thereof

Provided herein is anO polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

Polysaccharide and uses thereof

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]-β-D-Galp-(1→4)-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by

Immunogenic composition

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic(ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates ofpolysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of(EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Methods and compositions for immune protection against extra-intestinal pathogenic

A bioconjugate of anglucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying theO4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of anglucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additionalO-antigen polysaccharides to induce antibodies against anglucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic(ExPEC).

Bioconjugates ofO-antigen polysaccharides, methods of production thereof, and methods of use thereof

The present invention discloses modifiedClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example asaccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;3)-[[&#x3b1;-L-Rhap-(1&#x2192;2)]-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)]-&#x3b2;-L-Rhap-(1&#x2192;. Also provided are conjugates comprising a &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;3)-[[&#x3b1;-L-Rhap-(1&#x2192;2)]-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)]-&#x3b2;-L-Rhap-(1&#x2192;, immunogenic compositions, vaccines and their use in preventing or treating infection by

Methods of producing bioconjugates ofo-antigen polysaccharides, compositions thereof, and methods of use thereof

[object Object]

The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to aPcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of thePcrV carrier protein. The invention also disclosesPcrV proteins that contain glycosylation site consensus sequences.

PcrV-linked antigen vaccines

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;4)-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)-&#x3b2;-L-Rhap-(1&#x2192;. Also provided are conjugates comprising a &#x2192;4)-&#x3b2;-D-Glcp-(1&#x2192;4)-[Gro-(2&#x2192;P&#x2192;3)]-&#x3b2;-D-Galp-(1&#x2192;4)-&#x3b2;-L-Rhap-(1&#x2192;, immunogenic compositions, vaccines and their use in preventing or treating infection by

Growing community of inventors

Zurich, Switzerland

Stefan Jochen Kemmler